CTOs on the Move


 
iBio is an innovator biologics company developing therapeutics and vaccines for the betterment of human and animal health with pipeline candidates targeting systemic sceleroderma (IBIO-100), COVID-19 (IBIO-200 and IBIO-201), and classical swine fever (IBIO-400). iBio`s subsidiary, iBio CDMO is a global leader in plant-based manufacturing. It`s FastPharming® and FastGlycaneering™ platforms provide contract development and manufacturing services via its 130,000 square foot facility in Bryan, Texas. The speed and scalability of FastPharming make it an ideal choice for other innovator companies who want to rapidly produce biologics.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Similar Companies

GenomeDx Biosciences

Delivering Genomic Tests that Impact Treatment Decisions GenomeDx develops and commercializes genomic tests for prostate and other urologic cancers that have a direct impact on treatment decision-making, improve patient outcomes and ultimately reduce healthcare costs.

Alucent Biomedical

Alucent Biomedical, Inc. is a privately held biotechnology company headquartered in Salt Lake City, Utah and is the first company to bring a novel, locally delivered biotechnology treatment to a market traditionally dominated by medical device solutions. Alucent was founded by Avera Health to develop and market Natural Vascular Scaffolding (NVS). NVS is a first-of-a-kind combination drug-device therapy designed to assist the body in naturally opening and maintaining arterial patency.

British Columbia Cancer Agcy

British Columbia Cancer Agcy is a Vancouver, BC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ciitizen

Ciitizen is a platform that helps you collect, organize, and share your medical records digitally. Use it to get a second opinion, coordinate with a caregiver, and donate to research.

Immunomic Therapuetics

Immunomic Therapeutics, Inc. (ITI) is a privately-held clinical stage biotechnology company headquartered in Hershey, PA with lab facilities in Rockville, MD. ITI is developing next generation vaccines based on the patented Lysosomal Associated Membrane Protein, or LAMP, Technology. Our LAMP-Vax™ vaccine platform significantly increases the effectiveness of the immune response to nucleic acid vaccines while simplifying overall vaccine design and delivery, yielding safer, more cost-effective human and animal therapies. LAMP emerged from $20 million of NIH-funded research conducted by distinguished scientist Dr. Tom August at the Johns Hopkins University School of Medicine. ITI has the exclusive worldwide license to the LAMP technology patent estate and is commercializing ground-breaking next generation LAMP DNA vaccines, beginning with allergy, cancer and infectious disease.